Dr. Hamid Joseph Obeid , MD
Otolaryngology • Rome, NY
110 E Chestnut St
Rome, NY 134402866
This profile restates public CMS/NPPES data; T-MedInfo gives no medical advice — consult a licensed professional, and call 911 for emergencies.
-
NPI assigned on October 31, 2005; this date does not establish years in practice.
-
Published CMS data list 2,353 Original Medicare Part B services in 2024.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Published rows only; this is not a quality measure.
-
Published Part B service records, 2024:
- 99213 — Established patient outpatient office visit: 711 service units.
- 31231 — Diagnostic exam of nasal passages using an endoscope: 287 service units.
- 31237 — Biopsy or removal of nasal polyp or tissue using an endoscope: 240 service units.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Units differ by code; these are not visits or a measure of quality.
CPT® only copyright 2023 American Medical Association. All rights reserved. Service names are shortened from CPT Consumer Friendly Descriptors (CMS data, 2024). CPT notice
See all 28 records in the table · Guide: How to read Medicare Part B data
-
Published CMS data list 1,211 Medicare Part D prescriptions, including refills, in 2024.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024. Published rows only; this is not a quality measure.
-
Published Part D records, 2024:
- Dexamethasone Sodium Phosphate — 312 prescription fills, including refills.
- Fluticasone Propionate — 300 prescription fills, including refills.
- Azelastine Hcl — 121 prescription fills, including refills.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024. Drug names come from pharmacy claims. Listing a drug here is not an endorsement or a recommendation.
See all 22 records in the table · Guide: How to read Medicare Part D prescriber data
-
More Medicare Part B services than 80% of clinicians listed under Otolaryngology in New York (2024, 492 clinicians with data). Median for this group: 849. Middle half: 277 to 1,761.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Billing and prescribing volume is not a quality rating.
-
Medicare Part B services went from 2,383 in 2020 to 2,353 in 2024.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2020–2024.
Practice Location & Contact Primary Location
110 E Chestnut St
Rome, NY 134402866
Matched by practice address or phone in NPPES. A shared address or phone does not confirm that this clinician works there.
Medicare Profile & Education
Source: CMS Doctors and Clinicians National Downloadable File
1978
What Public CMS Data Show
Otolaryngology: NPPES taxonomy is a reported classification, not proof of board certification.
Medicare patients
346 people with Original Medicare in 2024
It gives a sense of how many people with Medicare this clinician treated that year.
Source: CMS, Medicare Physician & Other Practitioners – by Provider, 2024.
Medicare-allowed amount
About $539,893 in 2024
The total amount Medicare approved for these services in 2024. It includes what Medicare paid and what patients or their other insurance owed, such as the deductible and coinsurance.
It shows the total cost of this clinician's Original Medicare services under Medicare's fee rules.
What this does not show: Medicare-allowed amount
This is not the clinician's income. Part of it can go to a clinic or group practice, staff, equipment or drugs. It is not the price you will pay.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.
Paid by Medicare
About $412,229 in 2024
The part of the Medicare-allowed amount that Medicare itself paid in 2024, after patients' deductibles and coinsurance.
The gap between the allowed amount and this number is roughly what patients and their other insurance paid.
What this does not show: Paid by Medicare
This is not the clinician's income and not a measure of quality.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.
30-day fills
1,457 standardized 30-day fills in 2024
CMS converts prescriptions to 30-day supplies so they can be compared. A 90-day prescription counts as about three 30-day fills.
What this does not show: 30-day fills
It is not a count of patients and not a measure of quality.
Part D drug cost
$88,095 in 2024
The total cost of these prescriptions in 2024, paid by Medicare drug plans, patients and other payers together.
It shows the total spending on drugs this clinician prescribed, not what any one patient paid.
What this does not show: Part D drug cost
A higher cost often reflects the type of medicines a specialty uses. It is not your out-of-pocket cost and not a measure of quality.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024.
Open Payments general payments, program year 2025
All general payments: $1,864.78 across 33 records.
By nature of payment
- Travel and Lodging: $1,161.93 across 5 records.
- Food and Beverage: $702.85 across 28 records.
Reporting-company totals (3 largest of 9)
- Integra LifeSciences Corporation: $1,332.72 across 10 records.
- Sanofi and Genzyme US Companies: $148.93 across 5 records.
- AstraZeneca Pharmaceuticals LP: $90.20 across 4 records.
A reported payment does not necessarily mean the financial relationship is improper and is not a measure of care quality. Clinicians can review and dispute these records.
Source: Calculated by T-MedInfo from CMS Open Payments general-payment records for program year 2025 (published June 30, 2026).
Years since graduation
48 years (graduated 1978)
CMS Doctors and Clinicians data list 1978 as the year this clinician finished professional school.
It tells you roughly how long ago the clinician finished school.
What this does not show: Years since graduation
It is not the number of years in practice, and more years does not mean better care.
Source: CMS Doctors and Clinicians National Downloadable File.
NPI first issued
2005
The year this clinician's National Provider Identifier (NPI) was issued. An NPI is a unique 10-digit ID that US health care providers use for billing.
What this does not show: NPI first issued
NPIs have been issued only since 2005, so this year is not necessarily when the clinician started practicing.
Source: CMS NPPES NPI Registry.
Accepts Medicare assignment
CMS data list this clinician as accepting Medicare assignment. This means agreeing to take the Medicare-approved amount as full payment for covered services.
With Original Medicare, you usually pay only your deductible and coinsurance, and the office sends the claim to Medicare for you.
Medicare assignment applies to Original Medicare. It does not tell you whether the clinician is in a Medicare Advantage plan's network, accepts other insurance, or is taking new patients.
Source: CMS Doctors and Clinicians; Medicare.gov, “Does your provider accept Medicare as full payment?”
No telehealth indicator
CMS shows this indicator only when recent Medicare claims include telehealth services. The clinician may still offer telehealth; ask the office.
Source: CMS, Telehealth Indicator on Medicare Care Compare (fact sheet, January 2023); CMS Doctors and Clinicians.
Enrolled in Medicare (PECOS)
Dr. Obeid has a Medicare enrollment record in PECOS, the CMS system clinicians use to enroll so they can bill Medicare or order services for people with Medicare.
It does not show whether the clinician accepts assignment, is in your plan's network, or is taking new patients.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Can order Medicare-covered services
CMS lists Dr. Obeid as eligible to order or refer Medicare Part B clinical laboratory and imaging services, durable medical equipment (DME) and home health services for people with Medicare.
Medicare pays for these items and services only when they are ordered by an eligible clinician.
What this does not show: Can order Medicare-covered services
It does not mean the clinician offers these services directly.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Compared with the same specialty in Rome and New York
Billing and prescribing volume is not a quality rating.
Medicare Part B services
More Medicare Part B services than 80% of clinicians listed under Otolaryngology in New York (2024, 492 clinicians with data). Median for this group: 849. Middle half: 277 to 1,761.
Too few clinicians listed under Otolaryngology in Rome have Medicare Part B data for 2024 to compare.
Medicare-allowed amount
A higher Medicare-allowed amount than 95% of clinicians listed under Otolaryngology in New York (2024, 492 clinicians with data). Median for this group: $88,752. Middle half: $29,059 to $196,748.
Too few clinicians listed under Otolaryngology in Rome have Medicare Part B data for 2024 to compare.
Paid by Medicare
A higher Medicare payment amount than 95% of clinicians listed under Otolaryngology in New York (2024, 492 clinicians with data). Median for this group: $66,820. Middle half: $21,527 to $147,313.
Too few clinicians listed under Otolaryngology in Rome have Medicare Part B data for 2024 to compare.
Medicare Part D prescriptions
More Part D prescriptions than 80% of clinicians listed under Otolaryngology in New York (2024, 507 clinicians with data). Median for this group: 405. Middle half: 113 to 906.
Too few clinicians listed under Otolaryngology in Rome have Medicare Part D data for 2024 to compare.
Part D drug cost
A higher Part D drug cost than 90% of clinicians listed under Otolaryngology in New York (2024, 507 clinicians with data). Median for this group: $8,888. Middle half: $2,273 to $20,894.
Too few clinicians listed under Otolaryngology in Rome have Medicare Part D data for 2024 to compare.
2 active clinicians are listed under Otolaryngology with a practice address in Rome, NY (766 in New York).
Addresses are self-reported to NPPES and may be out of date.
CMS data by year
Changes may reflect reporting, coverage or privacy limits, not changes in care quality.
-
Medicare Part B services
Medicare Part B services varied from year to year: 2,383 in 2020 and 2,353 in 2024.
- 2020: 2,383
- 2021: 3,180
- 2022: 2,641
- 2023: 2,360
- 2024: 2,353
-
Medicare-allowed amount
Medicare-allowed amount increased 56% from $345,359 in 2020 to $539,893 in 2024.
- 2020: $345,359
- 2021: $549,211
- 2022: $538,365
- 2023: $401,378
- 2024: $539,893
-
Paid by Medicare
Paid by Medicare increased 56% from $264,394 in 2020 to $412,229 in 2024.
- 2020: $264,394
- 2021: $425,528
- 2022: $416,561
- 2023: $303,117
- 2024: $412,229
-
Medicare Part D prescriptions
Medicare Part D prescriptions decreased 20% from 1,520 in 2020 to 1,211 in 2024.
- 2020: 1,520
- 2021: 1,246
- 2022: 822
- 2023: 1,377
- 2024: 1,211
-
30-day fills
30-day fills decreased 20% from 1,831 in 2020 to 1,457 in 2024.
- 2020: 1,831
- 2021: 1,644
- 2022: 972
- 2023: 1,586
- 2024: 1,457
-
Part D drug cost
Part D drug cost increased 52% from $58,125 in 2020 to $88,095 in 2024.
- 2020: $58,125
- 2021: $68,145
- 2022: $18,027
- 2023: $37,898
- 2024: $88,095
-
Industry payments (Open Payments)
Industry payments (Open Payments) varied from year to year: $1,765.90 in 2021 and $1,864.78 in 2025.
- 2021: $1,765.90
- 2022: $5,580.12
- 2023: $1,185.09
- 2024: $2,812.63
- 2025: $1,864.78
Sources: CMS Medicare Physician & Other Practitioners (2024), CMS Medicare Part D Prescribers (2024), CMS Open Payments (2025), CMS Doctors and Clinicians, CMS NPPES NPI Registry. Specialty names follow the NUCC Health Care Provider Taxonomy.
Text: T-MedInfo · Report an error.
Pharma & Medical Device Financial Disclosures
Payments and other transfers of value that drug and medical device companies reported to CMS Open Payments
Program year 2025 (payments made January 1 – December 31, 2025): 33 records totaling $1,864.78.
| Manufacturer | Payment Nature | Product | Type | Amount ($) |
|---|---|---|---|---|
| Integra LifeSciences Corporation |
Travel and Lodging
Cash or cash equivalent
|
Integra | General | $333.21 |
| Integra LifeSciences Corporation |
Travel and Lodging
Cash or cash equivalent
|
Integra | General | $304.32 |
| Integra LifeSciences Corporation |
Travel and Lodging
Cash or cash equivalent
|
Integra | General | $253.70 |
| Integra LifeSciences Corporation |
Travel and Lodging
Cash or cash equivalent
|
Integra | General | $231.70 |
| Integra LifeSciences Corporation |
Food and Beverage
In-kind items and services
|
ACCLARENT AERA | General | $91.07 |
| Integra LifeSciences Corporation |
Travel and Lodging
Cash or cash equivalent
|
Integra | General | $39.00 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $37.78 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $35.07 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $33.99 |
| Neurent Medical Limited |
Food and Beverage
Cash or cash equivalent
|
NEUROMARK System | General | $32.14 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $30.69 |
| Regeneron Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $29.39 |
| Regeneron Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $27.82 |
| GlaxoSmithKline, LLC. |
Food and Beverage
In-kind items and services
|
NUCALA | General | $23.56 |
| AstraZeneca Pharmaceuticals LP |
Food and Beverage
In-kind items and services
|
TEZSPIRE | General | $23.55 |
| AstraZeneca Pharmaceuticals LP |
Food and Beverage
In-kind items and services
|
TEZSPIRE | General | $23.32 |
| AERIN MEDICAL INC. |
Food and Beverage
In-kind items and services
|
VIVAER STYLUS | General | $23.26 |
| Integra LifeSciences Corporation |
Food and Beverage
In-kind items and services
|
ACCLARENT AERA | General | $22.58 |
| AstraZeneca Pharmaceuticals LP |
Food and Beverage
In-kind items and services
|
FASENRA | General | $22.34 |
| GlaxoSmithKline, LLC. |
Food and Beverage
In-kind items and services
|
NUCALA | General | $22.01 |
| Integra LifeSciences Corporation |
Food and Beverage
In-kind items and services
|
ACCLARENT AERA | General | $21.57 |
| GlaxoSmithKline, LLC. |
Food and Beverage
In-kind items and services
|
NUCALA | General | $21.05 |
| AstraZeneca Pharmaceuticals LP |
Food and Beverage
In-kind items and services
|
FASENRA | General | $20.99 |
| Optinose US, Inc. |
Food and Beverage
In-kind items and services
|
Xhance | General | $19.30 |
| Integra LifeSciences Corporation |
Food and Beverage
In-kind items and services
|
ACCLARENT AERA | General | $19.24 |
(top 25 shown)
Source: CMS Open Payments, program year 2025, released June 30, 2026.
Performed Procedures & Service Volume
CPT® is a registered trademark of the American Medical Association. CPT codes, descriptions and other data only are copyright 2016–2023 American Medical Association. All rights reserved. Applicable FARS/HHSARS apply. Descriptions of CPT codes are the AMA's CPT Consumer Friendly Descriptors as published by CMS in the Medicare Physician & Other Practitioners – by Provider and Service data, 2017–2024; they are plain-language summaries, not for clinical coding or documentation. HCPCS Level II codes and descriptions are from CMS. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
| HCPCS Code | Services | Patients | Submitted Charge | Medicare Allowed |
|---|---|---|---|---|
|
99213
Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
|
711 | 313 | $113.00 | $82.84 |
|
31231
Diagnostic exam of nasal passages using an endoscope
|
287 | 159 | $250.00 | $165.63 |
|
31237
Biopsy or removal of nasal polyp or tissue using an endoscope
|
240 | 99 | $705.83 | $345.82 |
|
69209
Removal of impacted ear wax by washing
|
160 | 117 | $75.00 | $15.38 |
|
99153
Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes
|
157 | 27 | $46.20 | $9.47 |
|
92567
Test to assess middle ear function
|
141 | 79 | $36.65 | $14.77 |
|
92504
Exam of ear using a microscope
|
87 | 79 | $65.60 | $26.07 |
|
99204
New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
|
67 | 67 | $250.00 | $152.55 |
|
70486
Ct scan of face without contrast
|
53 | 52 | $500.00 | $79.21 |
|
92570
Comprehensive hearing test
|
46 | 46 | $75.00 | $29.23 |
|
31575
Diagnostic exam of voice box using a flexible endoscope
|
43 | 29 | $252.33 | $115.71 |
|
30117
Removal or destruction of growth of nose through nose
|
37 | 23 | $1754.55 | $442.82 |
|
31238
Control of bleeding of nose using an endoscope
|
33 | 22 | $425.00 | $329.49 |
|
30520
Reshaping of nasal cartilage
|
27 | 27 | $1337.15 | $304.61 |
|
99152
Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes
|
27 | 27 | $250.00 | $44.92 |
|
31295
Dilation of nasal sinus using an endoscope
|
24 | 24 | $3400.00 | $1947.41 |
|
31298
Dilation of sphenoid and frontal nasal sinus using an endoscope
|
24 | 24 | $7800.00 | $4119.92 |
|
31242
Destruction of nasal nerve by heat using an endoscope
|
23 | 23 | $3932.96 | $2166.02 |
|
99203
New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
|
23 | 23 | $175.00 | $102.17 |
|
30469
Repair of collapsed nasal valve
|
22 | 22 | $2559.84 | $1138.88 |
|
92557
Comprehensive hearing and speech recognition test
|
18 | 18 | $96.28 | $33.14 |
|
J3490
Unclassified drugs
|
18 | 18 | $2862.00 | $2752.66 |
|
31254
Partial removal of nasal sinus using an endoscope
|
16 | 16 | $632.38 | $340.74 |
|
30140
Removal of nasal air passage under lining tissue
|
15 | 15 | $929.08 | $198.84 |
|
99212
Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
|
15 | 13 | $69.00 | $51.34 |
(top 25 shown)
Source: CMS Part B by Provider and Service, 2024; services under 11 beneficiaries omitted by CMS. Privacy limits
Submitted charges are billed amounts, not a price quote for your visit.
Medicare Part D Prescribing Profile & Medications
Medicare Part D prescriptions filled, including refills, in 2024.
| Brand Name | Generic Name | Prescriptions | Day Supply | Total Cost | Patients |
|---|---|---|---|---|---|
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 312 | 5,229 | $14,932.62 | 119 |
| Fluticasone Propionate | Fluticasone Propionate | 300 | 12,525 | $4,269.01 | 121 |
| Azelastine Hcl | Azelastine Hcl | 121 | 5,050 | $2,653.40 | 52 |
| Dexamethasone | Dexamethasone | 48 | 425 | $311.14 | 44 |
| Ondansetron Odt | Ondansetron | 45 | 221 | $381.69 | 45 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 523 | $408.15 | 45 |
| Mometasone Furoate | Mometasone Furoate | 37 | 1,235 | $1,710.68 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 160 | $197.38 | 32 |
| Omeprazole | Omeprazole | 31 | 1,390 | $369.54 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | 1,050 | $149.46 | — |
| Alprazolam | Alprazolam | 26 | 98 | $20.99 | 26 |
| Montelukast Sodium | Montelukast Sodium | 25 | 1,290 | $171.54 | — |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 25 | 324 | $3,275.47 | 20 |
| Azithromycin | Azithromycin | 24 | 120 | $105.14 | 21 |
| Xhance | Fluticasone Propionate | 18 | 600 | $12,723.53 | — |
| Ipratropium Bromide | Ipratropium Bromide | 17 | 510 | $326.48 | — |
| Levofloxacin | Levofloxacin | 13 | 130 | $36.39 | 11 |
| Prednisone | Prednisone | 13 | 111 | $24.45 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 121 | $72.36 | 13 |
| Cevimeline Hcl | Cevimeline Hcl | 13 | 465 | $1,099.51 | — |
| Sucralfate | Sucralfate | 13 | 390 | $215.20 | — |
| Dupixent Syringe | Dupilumab | 13 | 364 | $44,641.35 | — |
Source: CMS Part D by Provider and Drug, 2024; rows below 11 claims omitted by CMS; volume isn’t quality. Privacy limits
Specialties & License Numbers Reported to NPPES
Self-certified to NPPES: 2023-09-15NUCC Taxonomy Code: 207Y00000X
An otolaryngologist-head and neck surgeon provides comprehensive medical and surgical care for patients with diseases and disorders that affect the ears, nose, throat, the respiratory and upper alimentary systems and related structures of the head and neck. An otolaryngologist diagnoses and provides medical and/or surgical therapy or prevention of diseases, allergies, neoplasms, deformities, disorders and/or injuries of the ears, nose, sinuses, throat, respiratory and upper alimentary systems, face, jaws and the other head and neck systems. Head and neck oncology, facial plastic and reconstructive surgery and the treatment of disorders of hearing and voice are fundamental areas of expertise.
Additional State Medicaid & Healthcare Payer Identifiers
Medicare (PECOS) Enrollment & Ordering Eligibility
Source: CMS PECOSPRACTITIONER - OTOLARYNGOLOGY
I20100824000962
NY
3779607056
Sources: CMS Provider Enrollment and Order and Referring. Medicare enrollment is a billing status, not an accreditation or quality rating.
Career & Practice History Timeline
Changes recorded in monthly NPPES data files: addresses, names, credentials, specialties and NPI status
Registered at 110 E CHESTNUT ST, ROME, NY 134402866 (Tel: 3153368302)
Registered at 110 E CHESTNUT ST, ROME, NY 134402866 (Tel: 3153368302)
NPI status registered as active in NPPES database
Registered at 107 E CHESTNUT ST, SUITE 105, ROME, NY 134402834 (Tel: 3153368302)
Registered at 107 E CHESTNUT ST, SUITE 105, ROME, NY 134402834 (Tel: 3153368302)
Recorded as HAMID OBEID, MD
Otolaryngology (license number reported to NPPES: NY 227019-1)
First registered as active Individual Practitioner in NPPES Database.
NPI Administrative Meta
Mailing Address
110 E Chestnut St
Rome, NY 134402866
Phone: 3153368302